Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st

Name	Symbol	Market	Type
Capital Group Fixed Income ETF Trust	AMEX:CGCP	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

Capital Group Fixed Income ETF Trust

AMEX:CGCP

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	22.48				0	09:09:54

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

0.00

0.00%

22.48

09:09:54

Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st

04/03/2009 12:30pm

PR Newswire (US)

Capital Group Fixed Inco... (AMEX:CGCP)
Historical Stock Chart

From Jun 2019 to Jun 2024

Click Here for more Capital Group Fixed Inco... Charts.

IRVINE, Calif., March 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), announced that the company will release results for its fourth quarter and full year ended December 31, 2008 prior to market open on Tuesday, March 31, 2009. The company also said that President Richard P. Lanigan and Senior Vice President and Chief Financial Officer William R. Abbott will host an investor conference call that day at 12:00 p.m. Eastern time (9:00 a.m. Pacific time) to review the company's financial results and business outlook. The call is open to all interested investors through a live audio web broadcast via the Internet at http://www.cardiogenesis.com/ and will also be available by dialing (800) 706-7745. The participant passcode is 47828764. The call will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast. About Cardiogenesis Corporation Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com/ or the direct to patient website at http://www.heartofnewlife.com/. DATASOURCE: Cardiogenesis Corporation CONTACT: William R. Abbott, Senior Vice President and Chief Financial Officer of Cardiogenesis Corporation, +1-949-420-1800 Web Site: http://www.cardiogenesis.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CGCP Capital Group Fixed Income ETF Trust